Cargando…
The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma
BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patien...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814718/ https://www.ncbi.nlm.nih.gov/pubmed/36620583 http://dx.doi.org/10.3389/fonc.2022.1076548 |
_version_ | 1784864198598066176 |
---|---|
author | Qin, Jiali Yang, Yang Du, Wei Li, Gang Wu, Yao Luo, Ruihua Liu, Shanting Fan, Jie |
author_facet | Qin, Jiali Yang, Yang Du, Wei Li, Gang Wu, Yao Luo, Ruihua Liu, Shanting Fan, Jie |
author_sort | Qin, Jiali |
collection | PubMed |
description | BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patients with follicular thyroid nodules(FTN) treated in Henan Cancer Hospital were analyzed by liquid chromatography-mass spectrometry (LC-MS). RESULTS: The analysis showed that the metabolite profiles of FTC tissues could be well distinguished from those of control tissues, and 6 kinds of lipids were identified respectively, including lysophosphatidic acid(LysoPA) [LysoPA(0:0/18:0),LysoPA(0:0/18:2(9Z,12Z)],LysoPA[20:4(8Z,11Z,14Z,17Z)/0:0)]; phosphatidic acid(PA) [PA(20:3(8Z,11Z,14Z)/0:0),PA(20:4(5Z,8Z,11Z,14Z)/0:0),PA(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)]; lysophosphatidylcholine(LPC) [LPC(18:1),LPC(16:0),LPC[16:1(9Z)/0:0],LPC(17:0),LPC[22:4(7Z,10Z,13Z,16Z),LPC(20:2(11Z,14Z); phosphatidylcholine(PC)(PC(14:0/0:0),PC(16:0/0:0); sphingomyelin(SM) (d18:0/12:0); fatty acid(FA)(18:1(OH3)]. There are 2 kinds of amino acids, including L-glutamate,L-glutamine.There are 3 other metabolites, including retinol,flavin adenine dinucleotide,androsterone glucuronide.Lipid metabolites are the main metabolites in these metabolites.The metabolic pathways related to FTC were analyzed by KEGG and HMDB, and 9 metabolic pathways were found, including 4 amino acid related metabolic pathways, 1 lipid metabolic pathways and 4 other related pathways. CONCLUSION: There are significant differences in many metabonomic characteristics between FTC and FTN, suggesting that these metabolites can be used as potential biomarkers. Further study found that LysoPA and its analogues can be used as biomarkers in the early diagnosis of FTC.It may be related to the abnormal metabolism of phospholipase D (PLD), the key enzyme of LysoPA synthesis caused by RAS pathway. At the same time, it was found that the metabolic pathway of amino acids and lipids was the main metabolic pathway of FTC. The abnormality of LysoPA may be the cause of follicular tumor carcinogenesis caused by lipid metabolic pathway. |
format | Online Article Text |
id | pubmed-9814718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98147182023-01-06 The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma Qin, Jiali Yang, Yang Du, Wei Li, Gang Wu, Yao Luo, Ruihua Liu, Shanting Fan, Jie Front Oncol Oncology BACKGROUND: To explore the metabolic differences of follicular thyroid carcinoma (FTC) by metabonomics, to find potential biomarkers for the diagnosis of FTC, and to explore the pathogenesis and diagnosis and treatment strategies of FTC. METHOD: The metabonomics of 15 patients with FTC and 15 patients with follicular thyroid nodules(FTN) treated in Henan Cancer Hospital were analyzed by liquid chromatography-mass spectrometry (LC-MS). RESULTS: The analysis showed that the metabolite profiles of FTC tissues could be well distinguished from those of control tissues, and 6 kinds of lipids were identified respectively, including lysophosphatidic acid(LysoPA) [LysoPA(0:0/18:0),LysoPA(0:0/18:2(9Z,12Z)],LysoPA[20:4(8Z,11Z,14Z,17Z)/0:0)]; phosphatidic acid(PA) [PA(20:3(8Z,11Z,14Z)/0:0),PA(20:4(5Z,8Z,11Z,14Z)/0:0),PA(20:5(5Z,8Z,11Z,14Z,17Z)/0:0)]; lysophosphatidylcholine(LPC) [LPC(18:1),LPC(16:0),LPC[16:1(9Z)/0:0],LPC(17:0),LPC[22:4(7Z,10Z,13Z,16Z),LPC(20:2(11Z,14Z); phosphatidylcholine(PC)(PC(14:0/0:0),PC(16:0/0:0); sphingomyelin(SM) (d18:0/12:0); fatty acid(FA)(18:1(OH3)]. There are 2 kinds of amino acids, including L-glutamate,L-glutamine.There are 3 other metabolites, including retinol,flavin adenine dinucleotide,androsterone glucuronide.Lipid metabolites are the main metabolites in these metabolites.The metabolic pathways related to FTC were analyzed by KEGG and HMDB, and 9 metabolic pathways were found, including 4 amino acid related metabolic pathways, 1 lipid metabolic pathways and 4 other related pathways. CONCLUSION: There are significant differences in many metabonomic characteristics between FTC and FTN, suggesting that these metabolites can be used as potential biomarkers. Further study found that LysoPA and its analogues can be used as biomarkers in the early diagnosis of FTC.It may be related to the abnormal metabolism of phospholipase D (PLD), the key enzyme of LysoPA synthesis caused by RAS pathway. At the same time, it was found that the metabolic pathway of amino acids and lipids was the main metabolic pathway of FTC. The abnormality of LysoPA may be the cause of follicular tumor carcinogenesis caused by lipid metabolic pathway. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9814718/ /pubmed/36620583 http://dx.doi.org/10.3389/fonc.2022.1076548 Text en Copyright © 2022 Qin, Yang, Du, Li, Wu, Luo, Liu and Fan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Qin, Jiali Yang, Yang Du, Wei Li, Gang Wu, Yao Luo, Ruihua Liu, Shanting Fan, Jie The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title | The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title_full | The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title_fullStr | The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title_full_unstemmed | The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title_short | The potential value of LC-MS non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
title_sort | potential value of lc-ms non-targeted metabonomics in the diagnosis of follicular thyroid carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814718/ https://www.ncbi.nlm.nih.gov/pubmed/36620583 http://dx.doi.org/10.3389/fonc.2022.1076548 |
work_keys_str_mv | AT qinjiali thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT yangyang thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT duwei thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT ligang thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT wuyao thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT luoruihua thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT liushanting thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT fanjie thepotentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT qinjiali potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT yangyang potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT duwei potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT ligang potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT wuyao potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT luoruihua potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT liushanting potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma AT fanjie potentialvalueoflcmsnontargetedmetabonomicsinthediagnosisoffollicularthyroidcarcinoma |